相似文献
1
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.
Int J Cancer. 2008 Jan 15;122(2):247-59. doi: 10.1002/ijc.23252.
2
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1418-29. doi: 10.1080/21645515.2015.1136039. Epub 2016 Feb 2.
3
Different spectra of therapeutic vaccine development against HPV infections.
Hum Vaccin. 2009 Oct;5(10):671-89. doi: 10.4161/hv.5.10.9370. Epub 2009 Oct 28.
4
Therapeutic human papillomavirus vaccination.
Public Health Genomics. 2009;12(5-6):331-42. doi: 10.1159/000214923. Epub 2009 Aug 11.
5
Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.
Otolaryngol Clin North Am. 2012 Aug;45(4):807-22. doi: 10.1016/j.otc.2012.04.005.
6
Therapeutic vaccines for high-risk HPV-associated diseases.
Papillomavirus Res. 2018 Jun;5:46-58. doi: 10.1016/j.pvr.2017.12.006. Epub 2017 Dec 19.
7
Emerging human papillomavirus vaccines.
Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19. doi: 10.1517/14728214.10.1.5.
8
Moving forward with human papillomavirus immunotherapies.
Hum Vaccin Immunother. 2016 Nov;12(11):2875-2880. doi: 10.1080/21645515.2016.1199302. Epub 2016 Jul 7.
9
Prospects for therapeutic HPV vaccines.
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S249-50. doi: 10.1016/j.ygyno.2005.07.098.
10
Therapeutic HPV DNA vaccines.
Expert Rev Vaccines. 2009 Sep;8(9):1221-35. doi: 10.1586/erv.09.76.
引用本文的文献
1
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics.
Viruses. 2025 Mar 14;17(3):417. doi: 10.3390/v17030417.
2
Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus.
Cancers (Basel). 2022 Sep 5;14(17):4339. doi: 10.3390/cancers14174339.
3
Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro.
J Gynecol Oncol. 2021 Jul;32(4):e59. doi: 10.3802/jgo.2021.32.e59. Epub 2021 Apr 6.
4
Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
Bioengineered. 2017 Jul 4;8(4):367-373. doi: 10.1080/21655979.2016.1230573. Epub 2016 Oct 18.
5
Therapeutic Vaccine Strategies against Human Papillomavirus.
Vaccines (Basel). 2014 Jun 13;2(2):422-62. doi: 10.3390/vaccines2020422.
6
Role of human papillomaviruses in carcinogenesis.
Ecancermedicalscience. 2015 Apr 29;9:526. doi: 10.3332/ecancer.2015.526. eCollection 2015.
7
A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.
J Transl Med. 2015 Mar 5;13:80. doi: 10.1186/s12967-015-0437-9.
8
Anti-tumor effects of genetic vaccines against HPV major oncogenes.
Hum Vaccin Immunother. 2015;11(1):45-52. doi: 10.4161/hv.34303. Epub 2014 Nov 1.
9
Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).
PLoS One. 2014 Nov 25;9(11):e113461. doi: 10.1371/journal.pone.0113461. eCollection 2014.
10
Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice.
Clin Vaccine Immunol. 2013 Jul;20(7):1027-33. doi: 10.1128/CVI.00721-12. Epub 2013 May 8.
本文引用的文献
1
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1179-84. doi: 10.1016/j.ijrobp.2011.10.060. Epub 2012 Feb 16.
2
A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.
J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1404-12. doi: 10.1111/j.1468-3083.2007.02441.x.
3
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Int J Cancer. 2007 Dec 15;121(12):2794-800. doi: 10.1002/ijc.23022.
4
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
JAMA. 2007 Aug 15;298(7):743-53. doi: 10.1001/jama.298.7.743.
5
A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
Gynecol Oncol. 2007 Sep;106(3):558-66. doi: 10.1016/j.ygyno.2007.05.038. Epub 2007 Jul 12.
6
Therapeutic vaccination for HPV induced cervical cancers.
Dis Markers. 2007;23(4):337-52. doi: 10.1155/2007/245146.
7
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Lancet. 2007 Jun 30;369(9580):2161-2170. doi: 10.1016/S0140-6736(07)60946-5.
8
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.
Gynecol Oncol. 2007 Sep;106(3):453-60. doi: 10.1016/j.ygyno.2007.04.038. Epub 2007 Jun 22.
9
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia.
Int J Cancer. 2007 Oct 15;121(8):1749-55. doi: 10.1002/ijc.22894.
10
Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia.
Gynecol Oncol. 2007 Sep;106(3):579-84. doi: 10.1016/j.ygyno.2007.05.019. Epub 2007 Jun 19.
Zotero 插件